Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers

Infection and Immunity

Volumn 64, Issue 10, 1996, Pages 4074-4077

  Cohen, Dani ^a,b,f   Ashkenazi, Shai ^a,b   Green, Manfred ^a,b   Lerman, Yehuda ^a,b   Slepon, Raphael ^a   Robin, Guy ^a   Orr, Nadav ^a   Taylor, David N ^c   Sadoff, Jerald C ^c,g   Chu, Chiayung ^d   Shiloach, Joseph ^e   Schneerson, Rachel ^d   Robbins, John B ^d  

^a Medical Corps   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f Merck Research Laboratories ^*  (Israel)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SHIGELLA VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; ISRAEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIGELLA; SHIGELLOSIS; VACCINATION;

EID: 10144223600     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.10.4074-4077.1996     Document Type: Article

References (25)

1. Ashkenazi, S., M. May-Zahav, G. Dinari, U. Gabbay, A. Zilberman, and Z. Samra. 1993. Recent trends in the epidemiology of Shigella infections. Clin. Infect. Dis. 17:897-899.
2. Chu, C. Y., B. Liu B, D. Watson D, S. C. Szu, D. Bryla, J. Shiloach, R. Schneerson, and J. Robbins. 1992. Preparation, characterization and immunogenicity of conjugates composed of the O-speciric polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect, Immun. 59:4450-4458.
3. Cohen, D., M. Green, C. Block, G. Lowell, and I. Ofek. 1989. Immunoglobulin M, A. and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27: 162-167.
4. Cohen, D., M. Green, C. Block, R. Slepon, R. Ambar, S. Wasserman, and M. M. Levine. 1991. Reduction of transmission of shigellosis by control of house flies (Musca domestica). Lancet 337:993-997.
5. Cohen, D., M. S. Green, C. Block, T. Rouach. and I. Ofek. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068-1071.
6. Cohen, D., M. S. Green, C. Block, R. Slepon, and I. Ofek. 1991. A prospective study on the association between serum antibodies to lipopolysaccharide and attack rate of shigellosis. J. Clin. Microbiol. 29:386-389.
7. Cryz, S. J., J. C. Sadoff, and E. Furer. 1988. Immunization with a Pseudomonas aeruginosa immunolype 5 O-polysaccharide-toxin A conjugate vaccine: eflect of a booster dose on antibody levels In humans. Infect. Immun. 56:1829-1830.
8. DuPont, H. L., R. B. Hornick, A. T. Dawkins, M. J. Synder, and S. B. Formal. 1969. The response of man to Shigella flexneri 2a. J. infect. Dis. 119:296-299.
9. DuPont, H. L., M. M. Levine, R. B. Hornick, and S. B. Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
10. Ekvall, E., S. Haeggmann, M. Kalin, B. Svenungsson, and A. A. Lindberg. 1983. Antibody response to Shigella sonnei infection determined by an enzyme-linked immunosorbent assay. Eur. J. Clin. Microbiol. 2:200-205.
11. Granoff, M. D., P. G. Shackelford, J. P. Pandey, and E. G. Boies. 1986. Antibody response to Haemophilus inftitenzue type b polysaccharide vaccine in relation to Km(l) and G2m(23) immunoglobin allotypes. J. Infect. Dis. 154:257-264.
12. Green, M. S., C. Block, D. Cohen, and P. Slater. 1991. Four decades of shigellosis in Israel - the epidemiology of a growing public health problem. Rev. Infect. Dis. 13:248-253.
13. Green, M. S., D. Cohen, C. Block, T. Rouach, and R. Dycian. 1987. A prospective epidemiologic study of shigellosis. Implications for the new Shigella vaccines. Isr. J. Med. Sci. 23:811-815.
14. Kenn, F. J., N. Alam, K. M. S. Aziz, and M. M. Rahaman. 1987. Dysentery, not watery diarrhoea, is associated with stunting in Banghieshi children. Human Nutrition: Clinical Nutrition 41C:243-249.
15. Herrington, D. A., L. Van De Verg, S. B. Formal, T. L. Hale, B. D. Tall, S. J. Cryz, E. C. Tramont, and M. M. Levine. 1990. Studies in volunteers to evaluate candidate Shigella vaccines. Further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353-357.
16. Keusch, T. G., and M. L. Bennish. 1991. Shigellosis, p. 593-620. In A. S. Evans and P. S. Brachman (ed.). Bacterial infections in humans. Plenum Medical Book Company, New York.
17. Lue, C., S. J. Prince, A. Fattom. R. Schneerson, J. B. Robbins, and J. Mestecky. 1990. Antibody-secreting peripheral blood lymphocytes after immunization with a conjugate consisting of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid. Infect. Immun. 58:2547-2554.
18. Miller, M. A., C. K. Meschievitz, G. A. Balanco, and R. F. Daum. 1995 Safety and immunogenicity of PRP-T combined with DPT. Pediatrics 95:522-526.
19. Orr, N., G. Robin, G. Lowell, and D. Cohen. 1992. Presence of specific immunoglobulin A secreting cells in peripheral blood following natural infection with Shigella sonnei. J. Clin. Microbiol. 30:2165-2168.
20. Robbins, J. B., C. Y. Chu, and R. Schneerson. 1992. Hypothesis for vaccine development: scrum IgG LPS antibodies confer protective immunity to nonlyphoidal Salmonellae and Shigellac. Clin. Infect. Dis. 15:346-361.
21. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protcin conjugates: a new generation of vaccines. J. Infect. Dis. 161:821-832.
22. Schneerson, R., J. B. Robbins, J. C. Parke, Jr., C. Bell, J. J. Schlesselman, A. Sutton, Z. Wang, G. Schiffman, A. Karpas, and J. Shiloach. 1986. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilux influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect. Immun. 52:519-528.
23. Smollan, G., and C. Block. 1992. Development of antimicrobial drug resistance among Shigellas isolated at an Israeli hospital from 1977 through 1990. Public Health Rev. 18:319-327.
24. Taylor, D. N., P. Echeverria, T. Pal, O. Scthabutr. S. Saiborisuth, S. Sricharmorn, B. Rowe, and J. Cross. 1986. The role of Shigella spp., enteroinvasive Escherichia coli. and other enteropathogens as causes of childhood dysentery in Thailand. J. Infect. Dis. 153:1132-1138.
25. Taylor, D. N., A. C. Trofa, J. Sadoff, C. Y. Chu. D. A. Bryla, J. Shiloach, D. Cohen, D. Ashkenazi, Y. Lerman. M. Egan, R. Schneerson, and J. Robbins. 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-spccific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2, and Shigella sonnei (plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678-3687.